In conclusion, the synergistic approach of combining URB597 and RSL3 presents a therapeutic strategy for RCC, harnessing the endocannabinoid system and ferroptosis pathways with the potential to target the PI3K-AKT pathway. The gene discussed is AKT1; the disease is renal cell carcinoma.